IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022
September 08 2022 - 9:03AM
Business Wire
The Company to host an earnings conference call
via webcast
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”)
(NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and
technology company, today announced that it will host a conference
call to discuss its quarterly results and recent business
highlights for first quarter fiscal year 2023, on Wednesday,
September 14, 2022, at 10:30 am Eastern Time. The financial results
will be issued in a press release prior to the call.
ImmunoPrecise management will host the conference call followed
by a pre-submitted question-and-answer period. Investors interested
in submitting questions ahead of the call are encouraged to email
the Company’s investor relations contact.
Conference Call:
Date: Wednesday, September 14, 2022 Time: 10:30 am Eastern
time
Participant Info:
Conference ID: 9236374 Participant Toll-Free Dial-In Number: 1
(888) 550-5658 Participant Toll Dial-In Number: 1 (646)
960-0289
Attendee URL: https://events.q4inc.com/attendee/349012238
The conference call will be webcast live and available for
replay via a link provided in the Events section of the company’s
IR pages at https://www.immunoprecise.com/investors.
Please call the conference telephone number five minutes prior
to the start time. An operator will register your name and
organization.
Anyone listening to the call is encouraged to read the company's
periodic reports on file with the Toronto Stock Exchange and
Securities and Exchange Commission, including the discussion of
risk factors and historical results of operations and financial
condition in those reports.
ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotherapeutic research and
technology company that leverages network biology, multi-omics
modelling and complex artificial intelligence systems to support
its proprietary technologies in bioplatform-based antibody
discovery. Services include highly specialized, full-continuum
therapeutic biologics discovery, development, and out-licensing to
support its business partners in their quest to discover and
develop novel biologics against the most challenging targets. For
further information, visit www.ipatherapeutics.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220908005667/en/
Investor contact: investors@immunoprecise.com
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Sep 2024 to Oct 2024
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Oct 2023 to Oct 2024